proprietary intellectual property and regulated medical technologies. MedX's platform generates and analyses high-fidelity skin health data using patented imaging, Teledermatology, and Photobiomodulation systems, creating a growing, defensible data asset and IP moat. MedX operates as an ISO 13485–certified medical device manufacturer and mainta...## MedX Announces Final Closing of Non-Brokered Private PlacementMISSISSAUGA, Ontario--([BUSINESS WIRE])--MedX Health Corp. ("MedX†or the "Company†) (TSX-V: MDX) ...

Core Insights - MedX Health Corp. is a data-driven health analytics company specializing in skin health data through proprietary technologies and regulatory compliance [1][16] - The company is preparing for a large-scale rollout of its technology platform in 2026 after significant investments in 2025 [3][14] Operational and Strategic Update - In fiscal 2025, MedX invested over CAD$2 million in technology development, intellectual property, and operational infrastructure [3] - The company made targeted hires in executive leadership and technology to enhance long-term commercial readiness [3] DermSecure® and SIAscopy® - MedX expanded its DermSecure® platform, now featuring approximately 85,000 clinically reviewed skin images, enhancing its data asset for AI-driven skin analysis [4] - The SIAscopy® technology remains the industry standard for non-invasive skin analysis, utilized by over 26 Contract Research Organizations (CROs) [10] Leadership Changes - In Q3 2025, MedX appointed a new CEO and its first CTO to consolidate technology development responsibilities [5] - A Chief Operating Officer was also appointed to enhance operational capabilities following a commercial agreement with Health Partners Group [6] Photobiomodulation Division - The Photobiomodulation division saw steady revenue growth in 2025, supported by product line expansion and regulatory compliance [7] - New laser products, including the Oralase dental laser and LumaVet veterinary system, were introduced to broaden market reach [8][9] CRO and Beauty & Aesthetics Activities - MedX's technology and services were provided to major global beauty brands, enhancing its CRO offerings through integrated imaging and data assets [10][11] - The company was released from an exclusive licensing agreement with Procter & Gamble, allowing it to pursue new commercial opportunities [12] Future Outlook - The company views 2025 as a foundational year for platform development and operational readiness, positioning itself for expanded commercial activities in 2026 [14]

Core Viewpoint - MedX Health Corp. has successfully completed the final closing of a non-brokered private placement, raising a total of $1,433,000 through the issuance of 19,106,666 units, which will be used for the development of its telemedicine platform and other corporate purposes [1][2]. Group 1: Private Placement Details - The final closing involved the issuance of 19,106,666 units at a price of $0.075 per unit, bringing the total units issued in this placement to 26,139,999 [1]. - Each unit consists of one fully paid common share and one-half share purchase warrant, with each whole warrant exercisable at $0.10 for one additional common share within one year [1]. - Insiders participated in the placement, acquiring a total of 21,806,666 units for $1,635,500, relying on exemptions from formal valuation and minority shareholder approval [1]. Group 2: Use of Funds - Funds raised from the private placement will be directed towards the continued development of the SIAscopy® technology on the DermSecure® telemedicine platform, expanding its launch into the occupational health market, and for general corporate purposes [2]. Group 3: Company Overview - MedX Health Corp. is a leader in non-invasive skin assessment and teledermatology, with its proprietary SIAscopy® technology enabling accurate imaging of skin lesions for rapid dermatologist review [3]. - The company's products are approved for use in multiple regions, including Canada, the U.S., Australia, and the European Union, highlighting its regulatory compliance and market reach [3]. - MedX's telemedicine platform allows healthcare professionals to assess skin conditions efficiently through its advanced imaging technology and secure patient management system [3].

Core Insights - MedX Health Corp. has appointed Dr. Symon D. Cotton as Strategic Advisor on AI and Product Development, enhancing its leadership in teledermatology and non-invasive skin analysis [1][5][6] Company Overview - MedX Health Corp. is a leader in non-invasive skin assessment and teledermatology, utilizing its proprietary SIAscopy® technology integrated into the DermSecure® platform for accurate imaging of skin lesions [6] - The company’s products are cleared for use in 38 territories worldwide, including Canada, the U.S., Australia, and the European Union [6] Appointment of Dr. Symon Cotton - Dr. Cotton is recognized for his contributions to medical technology innovation and has a background in engineering, biology, and computation [2][4] - He played a key role in the development of SIAscopy®, the first technology for non-invasive measurement of melanin, hemoglobin, and collagen in the skin [3] - His expertise in AI-driven analytics and medical imaging aligns with MedX's strategic goals to enhance diagnostic accuracy and scalability [4] Strategic Goals - Dr. Cotton aims to leverage MedX's imaging database and DermSecure® platform to improve early skin cancer detection globally [5] - The CEO of MedX, John Gevisser, emphasized that Dr. Cotton's experience will help maintain the company's leadership in skin optics and machine learning [5]